Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

Teva Pharmaceutical Industries (TEVA) reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Adjusted earnings declined 29% year over year.See the Zacks Earnings Calendar to stay ahead of market-making news.Revenues for the fourth quarter were $4.23 billion, beating the Zacks Consensus Estimate of $4.10 billion. However, total revenues declined 5% from the year-ago quarter on both reported and constant currency basis. The decline is mainly ...

Stock Performance - Shares of Teva Pharmaceutical Industries lost 13.5% as of 1:15 p.m. ET, underperforming the S&P 500 and Nasdaq Composite, which lost 0.5% and 0.9%, respectively [1] Financial Results - Teva reported Q4 sales of $4.2 billion and fiscal year 2024 sales of $16.5 billion, up from 2023's revenue of $15.9 billion, slightly exceeding expectations [2] - Q4 EPS was $0.71, down significantly from Q4 2023's $1.00 but slightly exceeding the expected $0.70 [2] Guidance and Investor Sentiment - The company's 2025 EPS forecast disappointed investors, with the high end of the range ($2.65) coming in below the expected $2.76 [3] Strategic Initiatives - Teva is implementing its "Pivot to Growth strategy," focusing on cost reduction through reorganization, generics, and R&D pipeline success, though the latter has no guarantees or clear timeline [4] - The company has key drugs in later stages of trials, including treatments for ulcerative colitis and Crohn's disease, which show promise but require significant effort [5]

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1% on Wednesday.The Dow traded down 0.16% to 44,778.55 while the NASDAQ fell 1% to 19,537.19. The S&P 500 also fell, dropping, 0.54% to 6,034.67.Check This Out: Jim Cramer: This Industrial Stock Is ‘Absolutely Terrific’, First Solar Is ‘Very Inexpensive’Leading and Lagging SectorsConsumer staples shares surged by 0.7% on Wednesday.In trading on Wednesday, information technology shares fell by 1.9%.Top HeadlineU.S. c ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2024 Earnings Conference Call January 29, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric Hughes - Head of R&D & Chief Medical Officer Eli Kalif - CFO Conference Call Participants Umer Raffat - Evercore ISI Jason Gerberry - Bank of America David Amsellem - Piper Sandler Balaji Prasad - Barclays Ash Verma - UBS Yifeng Liu - HSBC Glen Santangelo - Jefferies Chris Schulz - J.P. Morgan Operator Hello, a ...

Teva Pharmaceutical Industries Ltd. (TEVA) reported $4.23 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 5.1%. EPS of $0.71 for the same period compares to $1.00 a year ago.The reported revenue represents a surprise of +3.13% over the Zacks Consensus Estimate of $4.1 billion. With the consensus EPS estimate being $0.70, the EPS surprise was +1.43%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street exp ...

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $4.2 billion, a decrease of 5% compared to Q4 2023. Excluding a one-time payment from Sanofi, revenue increased by 7% [41][42] - Adjusted EBITDA for the year was $4.8 billion, up 9%, and non-GAAP EPS was $2.49, up 10% [9][39] - Free cash flow increased by 10% to $2.1 billion, and net debt to EBITDA ratio improved to approximately 3 times [9][50] Business Line Data and Key Metrics Changes - The Innovative business grew significantly, with AUSTEDO up 36% to nearly $1.7 billion, AJOVY up 18% to over $500 million, and Uceti reaching $117 million, exceeding guidance [10][12][14] - The Generics business saw an 11% increase, totaling approximately $9.5 billion, while the API business grew by 3% [10][20] Market Data and Key Metrics Changes - The U.S. market for AUSTEDO showed a 34% growth, contributing significantly to the overall performance [11] - International markets delivered a 15% growth, while Europe experienced mid-single-digit growth [22] Company Strategy and Development Direction - The company is focused on its "Pivot to Growth" strategy, which includes four pillars: delivering on growth engines, stepping up innovation, creating a sustainable generics powerhouse, and focusing the business [5][4] - Plans for 2025 include launching seven biosimilars in the U.S. and four in Europe, alongside a commitment to improve operational efficiency [19][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a 5% CAGR by 2027, citing strong growth in innovative products and a return to growth in the generics business [8][51] - The company is mindful of industry dynamics, including the Inflation Reduction Act's impact on the U.S. market, and is adjusting its financial guidance accordingly [54][56] Other Important Information - The company received a one-time payment of $500 million from Sanofi in Q4 2023, which positively impacted revenue and adjusted EBITDA [40] - Credit ratings agencies have upgraded the company's ratings, reflecting improved growth prospects and a strengthened balance sheet [51] Q&A Session Summary Question: What is the EBITDA trajectory going forward? - Management indicated that the partnership with Sanofi involves a 50-50 share of operational expenses, which will support the Duvequito program. They aim to grow EBITDA while investing in key areas [64][66] Question: Can you clarify the guidance for AUSTEDO and the impact of the IRA? - Management acknowledged that the IRA redesign affects AUSTEDO and noted that while they expect strong prescription growth, they must navigate the immediate impacts of the redesign [80][82] Question: How will the company address the loss of Revlimid sales? - Management plans to offset Revlimid's decline with new product launches, including 16 complex generics and several biosimilars, while maintaining growth in the innovative business [94][96] Question: Any updates on the lawsuit against CMS? - Management stated they cannot provide specific details due to ongoing litigation but will share updates as they become available [97]

Financial Performance & Growth - Teva's Q4 2024 revenues were $4229 million, a decrease of 5% compared to Q4 2023, but full year 2024 revenues increased by 4% to $16544 million[70] - Global generics revenue increased by 11% to $9461 million in 2024[15] - Teva API revenue increased by 3% to $553 million in 2024[9] - Free cash flow for FY 2024 was $2068 million, a decrease of 13% compared to $2387 million in FY 2023[70] - The company is targeting mid-single digit percentage revenue growth (CAGR) from 2023-2027[11] Key Products Performance - AUSTEDO U S revenues increased by 34% compared to 2023, reaching $1642 million[9, 18] - UZEDY revenues reached $117 million in 2024, exceeding the outlook of approximately $100 million[9, 20] - AJOVY global revenues in Q4 2024 were $142 million, representing an 18% growth[24, 25] Pipeline & Innovation - Duvakitug (anti-TL1A) Phase II trial showed positive results, with Phase III initiation targeted for 2025[9, 28] - Olanzapine LAI completed targeted injections in Phase III with no Post-Injection Delirium/Sedation Syndrome (PDSS), with long-term study full safety presentation expected in H1 2025[9, 28] - DARI (ICS/SABA) Phase III clinical trial sites activation exceeded 91%[9] Financial Health - Gross debt decreased to $178 billion as of December 31, 2024[74, 125] - Net debt decreased to $145 billion as of December 31, 2024[74, 125]

EXHIBIT 99.1 Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth Q4 2024 and FY 2024 highlights: | | Q4 2024 | FY 2024 | | --- | --- | --- | | Revenues | $4.2 billion | $16.5 billion | | GAAP loss per share | $0.19 | $1.45 | | Non-GAAP diluted EPS | $0.71 | $2.49 | | | | $1,247 | | Cash flow generated from operating activities | $575 million | million | | | | $2,068 | | Free cash ...

Core Insights - Teva Pharmaceutical Industries Ltd. reported a transformative year in 2024, achieving a second consecutive year of growth driven by generic and innovative products [3][5] - The company generated revenues of $16.5 billion in FY 2024, reflecting a 6% increase in local currency terms compared to 2023 [5][8] - The company anticipates further progress in 2025, particularly in innovative growth drivers and complex generics [3][6] Financial Performance - Q4 2024 revenues were $4.2 billion, a decrease of 5% compared to Q4 2023 [26] - FY 2024 GAAP loss per share was $1.45, while non-GAAP diluted EPS was $2.49 [1][18] - Cash flow generated from operating activities in FY 2024 was $1.247 billion, down from $1.368 billion in 2023 [22][24] Product Performance - AUSTEDO revenues exceeded $1.6 billion, surpassing the 2024 outlook, while AJOVY generated $507 million, an 18% increase in local currency terms [5][8] - The generics business grew by 15% in the U.S. and 6% in Europe compared to 2023 [5][8] - Duvakitug (anti-TL1A) achieved positive Phase 2b results, with Phase 3 trials expected to initiate in 2025 [3][5] Strategic Initiatives - The "Pivot to Growth" strategy focuses on four key pillars: delivering growth engines, stepping up innovation, sustaining the generics business, and optimizing the portfolio [7][12] - The company is progressing with the sale of its active-pharmaceutical ingredient (API) business, which has been classified as held for sale [12][25] Segment Results - In the U.S. segment, revenues decreased by 13% to $1.975 billion in Q4 2024, primarily due to an upfront payment received in Q4 2023 [46][66] - The Europe segment reported revenues of $1.353 billion, a 1% increase compared to Q4 2023, with generic products driving growth [67][69] Research and Development - R&D expenses in FY 2024 were $998 million, a 5% increase compared to 2023, reflecting continued investment in innovative pipelines [11][30] - The company is advancing its late-stage innovative pipeline, particularly in immunology and neuroscience [11][12]